
Extreme heat represents an important clinical challenge for patients with cardiovascular disease (CVD). Individuals with heart failure (HF) may be particularly vulnerable because heat dissipation requires cutaneous vasodilation, increased skin blood flow, and sweating, whereas HF may limit cardiovascular reserve and increase susceptibility to hypotension, renal dysfunction, and electrolyte disturbances. Risk is further amplified by advanced age, chronic kidney disease (CKD), frailty, cognitive impairment, limited access to cooling, and the use of medications that influence volume status, blood pressure (BP), or thermoregulation. Observational evidence links high ambient temperatures with cardiovascular morbidity and mortality, and recent HF-specific data support an association between short-term heat exposure and increased mortality. However, evidence directly guiding the clinical management of chronic HF during heatwaves remains limited. No randomized controlled trial (RCT) has established whether or how guideline-directed medical therapy (GDMT) should be modified solely in response to hot weather. This focused narrative review proposes a cautious, phenotype-driven approach. Local heat alerts should prompt anticipatory risk assessment, patient education, and temporary intensification of surveillance, whereas treatment changes should be determined by the interaction between symptoms, congestion, BP, weight, oral intake, urine output, renal function, and electrolytes rather than ambient temperature alone. Telemonitoring may provide an enabling infrastructure for this strategy, although heat-alert-triggered remote management has not been prospectively validated. Extreme heat should therefore prompt increased clinical vigilance rather than automatic medication withdrawal. Prospective studies are needed to validate heat-specific monitoring pathways, hydration strategies, and medication-review protocols in chronic HF.
Cardiac amyloidosis, historically characterized as a restrictive cardiomyopathy, is now understood as a multi-compartmental disorder. Atrial amyloid infiltration—whether ANP-derived isolated atrial amyloidosis secondary to atrial stretch, or primary atrial ATTR infiltration—produces an atrial cardiomyopathy that frequently manifests as atrial fibrillation and a thrombogenic substrate even in sinus rhythm. Cardiac amyloidosis exhibits a high prevalence in heart failure, particularly among elderly patients presenting with preserved ejection fraction. Furthermore, TTR amyloid frequently coexists with degenerative aortic stenosis, and amyloid deposits are also found in the coronary microcirculation and the aorta. Given the current availability of efficacious treatments for amyloidosis, the recognition of these diverse clinical manifestations is paramount for achieving accurate diagnosis, appropriate risk stratification, and timely therapeutic intervention to enhance cardiovascular outcomes. This review frames amyloid cardiovascular disease as a multisystem process affecting the myocardium, atria, valves, and vasculature—often with extracardiac red flags—rather than solely as an infiltrative ventricular cardiomyopathy. Actionable implications currently concentrate on ventricular ATTR/AL cardiomyopathy and concomitant aortic stenosis; coronary and aortic medial deposits remain mechanistically important research targets rather than independently treatable lesions. Amyloid cardiovascular disease is now viewed as a multifaceted clinical spectrum, with pathology extending beyond the ventricular myocardium. This holistic paradigm includes atrial and ventricular amyloid cardiomyopathy (CM), TTR amyloid deposition in heart failure (HF) patients, cardiac valves (especially the aortic valve), coronary macro- and microcirculation, and the aorta. Left ventricular (LV) dilation, while infrequently observed in AL amyloid cardiomyopathy (AL-CM), may result from advanced-stage myocardial burnout, concomitant comorbidities, genetic predisposition, or atypical phenotypes.
A substantial gap persists between scientific evidence and clinical practice in heart failure (HF). Digital solutions have emerged as promising strategies to accelerate the implementation of evidence-based therapies. This mini-review examines the results of the EMAIL-HF study, a registry-based, randomized, controlled, parallel-group clinical trial conducted in Denmark that included patients aged 20 years or older with a diagnosis of HF irrespective of left ventricular ejection fraction, who were not receiving SGLT2 inhibitors (SGLT2i). Participants were randomized to usual care or a digital strategy consisting of an e-mailed letter with information on SGLT2i, followed by contact with an HF specialist. The primary endpoint was the proportion of patients redeeming a prescription for dapagliflozin or empagliflozin within 6 months of randomization and the secondary endpoint was a composite of time to first HF hospitalization or death from any cause. The digital strategy significantly increased SGLT2i initiation within 6 months, although no difference in HF hospitalization or all-cause mortality was observed during the 24-month follow-up. Whether these strategies can translate modest improvements in treatment uptake into sustained, scalable, and cost-effective gains across diverse healthcare systems remains uncertain.
Hyperkalemia, commonly defined as a serum potassium concentration > 5.0 mEq/L, is a frequent and clinically important complication in patients with chronic heart failure (HF), particularly those with chronic kidney disease receiving guideline-directed medical therapy (GDMT). Its impact extends beyond the electrolyte abnormality itself because recurrent hyperkalemia may lead to underuse, dose reduction, or discontinuation of prognostically important therapy. The risk is not uniform across GDMT classes: mineralocorticoid receptor antagonists carry the greatest direct risk, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and angiotensin receptor-neprilysin inhibitors also increase risk, whereas sodium-glucose cotransporter-2 inhibitors may reduce serious hyperkalemia. Sodium zirconium cyclosilicate (SZC) effectively lowers serum potassium and randomized evidence supports its use to maintain normokalemia and facilitate spironolactone optimization. However, a reduction in mortality or HF hospitalization has not been established. Emerging observational data suggest additional potential roles in supporting individualized dietary liberalization, improving gastrointestinal tolerability relative to traditional resins, and preventing recurrent hyperkalemia after treatment withdrawal. These findings should be interpreted cautiously because several supporting studies are small, nonrandomized, and potentially affected by residual confounding. Long-term treatment also requires attention to sodium exposure and edema, particularly in patients with HF or advanced kidney disease. This review integrates class-specific hyperkalemia risk, practical potassium thresholds, efficacy and safety evidence, comparison with patiromer, health-economic considerations, and remaining evidence gaps to provide a clinically applicable framework for individualized potassium management in HF.
Heart failure remains a leading cause of hospitalization, readmission, and health care utilization worldwide. Although advances in pharmacologic and device-based therapies have improved outcomes, clinical management continues to rely largely on episodic assessments that often identify decompensation only after symptoms emerge. This reactive paradigm limits opportunities for early intervention and contributes to persistently high hospitalization rates. Recent advances in wearable and remote sensing technologies have enabled continuous, ambulatory assessment of cardiovascular physiology. Implantable, subcutaneous, and wearable sensors now provide longitudinal data on hemodynamics, impedance, heart rhythm, respiratory patterns, physical activity, and functional status. Emerging evidence demonstrates that these technologies can detect physiologic deterioration days to weeks before overt clinical worsening, creating the potential to shift heart failure care from symptom-driven response to anticipatory management. This review synthesizes current evidence supporting remote sensing technologies in heart failure, emphasizing physiologic relevance, predictive capability, and clinical actionability.